Erythematosus in Medical Technology
Navigation Links
Erythematosus in Medical Technology
... patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, ... agreement.
About Systemic Lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic, life-threatening autoimmune ...
... with active moderate and severe systemic lupus erythematosus (SLE). These findings were presented at the ... investigation for the treatment of systemic lupus erythematosus (SLE). CD22 is a B-cell specific surface protein ... Morris Plains, NJ, USA. About systemic lupus erythematosus (SLE) Systemic ...
... of care in patients with active systemic lupus erythematosus (SLE). The results will be the subject of an oral ... under the agreement. About Systemic Lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening disease. The ...
... the results of our two Phase 3 trials of LymphoStat-B in systemic lupus erythematosus (SLE) in July and November, respectively, and expect to file marketing ... trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE). The Company expects to report the first Phase 3 data for ...
... with standard of care in patients with serologically active systemic lupus erythematosus (SLE). The results are the subject of a number of oral and poster ... Foundation of America at http://www.lupus.org or the European Lupus erythematosus Federation at http://www.elef.rheumanet.org . For more information about ...
... November 10, 2007 from 8:00am to 4:30pm EST. About Systemic Lupus erythematosus (SLE)(1) SLE is a chronic autoimmune disease that affects nearly ... safety and tolerability of CPG 52364 for the treatment of Systemic Lupus erythematosus (SLE); confirmation of TLR7/8/9 as a target for SLE; ; Coley's ability to ...
... occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history. Systemic Lupus erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus. Lithium Interaction Lithium ...
... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: Anne ...
... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: Anne Bowdidge (650) ...
... in autoimmune and inflammatory diseases." TRU-015 and SBI-087 for SLE Wyeth intends to pursue clinical evaluation of SBI-087 in Systemic Lupus erythematosus (SLE) and an investigational new drug filing is expected by the end of the year. As a result, Wyeth no longer intends to evaluate TRU-015 in a ...
... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . Contact: Anne Bowdidge (650) 218-6900 ...
... completion of a Phase Ib clinical study of TRX1, a novel humanized anti-CD4 monoclonal antibody (MAb), in subjects with refractory cutaneous lupus erythematosus (CLE). The Phase Ib study was designed to assess the safety, tolerability, and pharmacokinetics of TRX1. Tolerx has received a milestone payment from ...
... cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced ...
... of life in patients with active systemic lupus erythematosus (SLE). The 52-week and 76-week results of the ... under the agreement. About Systemic Lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening disease. The ...
... (blood forming) stem cells (HSC) in a mouse study of Systemic Lupus erythematosus (SLE). Subjects that underwent this procedure exhibited improved overall ... blood disorders and autoimmune disease. About Lupus Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the ...
... Levitra((R)), Cialis((R))) could result in severe hypotension. Treatment with hydralazine may produce a clinical picture simulating systemic lupus erythematosus (SLE) including glomerulonephritis. If SLE-like symptoms occur, discontinuation of BiDil should be considered. Residua have been detected many ...
... been reported in Rituxan-treated patients including those with hematologic malignancies or with certain autoimmune diseases such as systemic lupus erythematosus (SLE), an indication for which Rituxan has not been approved. About Rituxan Rituxan is a therapeutic antibody being studied in ...
... been reported in Rituxan-treated patients including those with hematologic malignancies or with certain autoimmune diseases such as systemic lupus erythematosus (SLE), an indication for which Rituxan has not been approved. About Rituxan Rituxan is a therapeutic antibody being studied in ...
... necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, SLE and B-cell malignancies. ...
... of steroid. Lund, June 18, 2007 Active Biotech AB (Publ) Sven Andréasson President & CEO About SLE and 57-57 Systematic Lupus erythematosus (SLE) is a disease of the connective tissues that can cause inflammation and damage to the connective tissue in many different organs. The disease, ...
... will host a conference call today at 9:30 a.m. ET (6:30 a.m. PT) to discuss these preliminary results. About Lupus Nephritis Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered ...
... with active moderate and severe systemic lupus erythematosus (SLE). These findings were presented at the ... investigation for the treatment of systemic lupus erythematosus (SLE). CD22 is a B-cell specific surface protein ... Morris Plains, NJ, USA. About systemic lupus erythematosus (SLE) Systemic ...
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
... in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and ... Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening autoimmune ... at http://www.lupus.org or the European Lupus erythematosus Federation at http://www.elef.rheumanet.org . ...Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
... in patients with active systemic lupus erythematosus (SLE). LymphoStat-B is being developed by HGS and ... Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening autoimmune ... at http://www.lupus.org or the European Lupus erythematosus Federation at http://www.elef.rheumanet.org . ...... of care in patients with active systemic lupus erythematosus (SLE). The results will be the subject of an oral ... under the agreement. About Systemic Lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening disease. The ...
... the results of our two Phase 3 trials of LymphoStat-B in systemic lupus erythematosus (SLE) in July and November, respectively, and expect to file marketing ... trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE). The Company expects to report the first Phase 3 data for ...
... with standard of care in patients with serologically active systemic lupus erythematosus (SLE). The results are the subject of a number of oral and poster ... Foundation of America at http://www.lupus.org or the European Lupus erythematosus Federation at http://www.elef.rheumanet.org . For more information about ...
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
... Lead drug candidate may help patients with Systemic Lupus erythematosus (SLE) SOUTH SAN FRANCISCO, Calif., April ... levels that decreased following the onset drug treatment. Systemic Lupus erythematosus (SLE) Lupus is an autoimmune disease, which affects nearly 2 ...Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
... genetic study has identified multiple genes linked to systemic lupus erythematosus (SLE), or lupus, a debilitating autoimmune disease that affects an ... Lupus Research (ALR) formed and supported the International Systemic Lupus erythematosus Genetics (SLEGEN) Consortium, charging scientists with searching for ...... November 10, 2007 from 8:00am to 4:30pm EST. About Systemic Lupus erythematosus (SLE)(1) SLE is a chronic autoimmune disease that affects nearly ... safety and tolerability of CPG 52364 for the treatment of Systemic Lupus erythematosus (SLE); confirmation of TLR7/8/9 as a target for SLE; ; Coley's ability to ...
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results
... lupus. To learn more about lupus clinical trials, log on to www.LupusTrials.org . About Lupus Systemic lupus erythematosus (SLE) or lupus, one of the nation's least recognized major diseases, is a chronic and potentially fatal autoimmune disorder that affects more than ...... occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history. Systemic Lupus erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus. Lithium Interaction Lithium ...
... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: Anne ...
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
... today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the ...Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
... LymphoStat-B(R) (belimumab), a human monoclonal antibody that neutralizes BLyS(TM) (B-lymphocyte stimulator), for the treatment of systemic lupus erythematosus SLE In November 2007, Phase 2 results were presented at the Annual Scientific Meeting of the American College of Rheumatology, which demonstrated ...... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . MEDIA CONTACT: Anne Bowdidge (650) ...
... in autoimmune and inflammatory diseases." TRU-015 and SBI-087 for SLE Wyeth intends to pursue clinical evaluation of SBI-087 in Systemic Lupus erythematosus (SLE) and an investigational new drug filing is expected by the end of the year. As a result, Wyeth no longer intends to evaluate TRU-015 in a ...
... of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com . Contact: Anne Bowdidge (650) 218-6900 ...
... completion of a Phase Ib clinical study of TRX1, a novel humanized anti-CD4 monoclonal antibody (MAb), in subjects with refractory cutaneous lupus erythematosus (CLE). The Phase Ib study was designed to assess the safety, tolerability, and pharmacokinetics of TRX1. Tolerx has received a milestone payment from ...
... cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced ...
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
... cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced ...... of life in patients with active systemic lupus erythematosus (SLE). The 52-week and 76-week results of the ... under the agreement. About Systemic Lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic, life-threatening disease. The ...
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
... of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). Analyses of interim antibody data indicate that ... known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and any other drug candidate that we may develop, including the ...... (blood forming) stem cells (HSC) in a mouse study of Systemic Lupus erythematosus (SLE). Subjects that underwent this procedure exhibited improved overall ... blood disorders and autoimmune disease. About Lupus Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the ...
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
... similar expression. The analyses of clinical results of Riquent, previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and any other drug candidate that we may develop, including the results of any trials or models that are ongoing or that we may initiate ...... Levitra((R)), Cialis((R))) could result in severe hypotension. Treatment with hydralazine may produce a clinical picture simulating systemic lupus erythematosus (SLE) including glomerulonephritis. If SLE-like symptoms occur, discontinuation of BiDil should be considered. Residua have been detected many ...
... been reported in Rituxan-treated patients including those with hematologic malignancies or with certain autoimmune diseases such as systemic lupus erythematosus (SLE), an indication for which Rituxan has not been approved. About Rituxan Rituxan is a therapeutic antibody being studied in ...
... been reported in Rituxan-treated patients including those with hematologic malignancies or with certain autoimmune diseases such as systemic lupus erythematosus (SLE), an indication for which Rituxan has not been approved. About Rituxan Rituxan is a therapeutic antibody being studied in ...
... necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, SLE and B-cell malignancies. ...
... of steroid. Lund, June 18, 2007 Active Biotech AB (Publ) Sven Andréasson President & CEO About SLE and 57-57 Systematic Lupus erythematosus (SLE) is a disease of the connective tissues that can cause inflammation and damage to the connective tissue in many different organs. The disease, ...
... will host a conference call today at 9:30 a.m. ET (6:30 a.m. PT) to discuss these preliminary results. About Lupus Nephritis Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered ...
Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
... complex (anti-AtherOx) with vascular thrombosis (particularly with arterial thrombosis) in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and anti-phospholipid syndrome. The study looked at 113 SLE patients (94 with secondary anti-phospholipid syndrome and 19 without) ...Other ContentsbiologistbiologistbiologistbiologistbiologistbiotechnologybiotechnologybiotechnologybiotechnologybiotechnologybiotechnologybiomechanicsbonebonebonebonebonebonebonebonebonebonebiophysicsbiophysicsbiopolymerbiopolymerblastblastcountcountcountcountcountcountcountOther TagsLeadersLeadersCitizensNettlesOptimisticReallyOffshore
(Date:12/1/2009)...h. -- Time-lapsed video of individual breast tissu...ife of a cell: a protein that cycles between two m...searchers a more complete view of the internal sig...s that go awry in cancer and are targets of drug d...s respond to growth factors, travels back and fort...
(Date:12/1/2009)... just for listening to the radio anymore. They,re .... Research from North Carolina State University is...ting shape-shifting antennas that open the door to...safety to military deployment. , Modern antennas...re limitations to how far they can be bent and ho...
(Date:11/30/2009)...organisation is needed to monitor the commitments ...hagen to cut their deforestation rates, according ...ng government agencies and research groups have fa...e images of the Earth,s surface collected each wee...published by Dr Alan Grainger in the Proceedings ...
Breaking Biology News(10 mins):ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4Shape shifters: Researchers create new breed of antennas 2World forest observatory needed to monitor vital role of forests in climate deal 2New Momentum Teams With Oracle to Help Reduce Counterfeiting in the Life Sciences Industry 5248 1New Momentum Teams With Oracle to Help Reduce Counterfeiting in the Life Sciences Industry 5248 2Ethnic background may be associated with diabetes risk 58933 1Ethnic background may be associated with diabetes risk 58933 2Optical Express Launches Television Advertisement for the Cosmetic Clinic 58929 1Optical Express Launches Television Advertisement for the Cosmetic Clinic 58929 2Optical Express Launches Television Advertisement for the Cosmetic Clinic 58929 3(Date:12/2/2009)...l phones that direct microwave signal transmission...from Aerius International Ltd. , ... new cell phones that direct microwave signal tran...ly 2010 from Aerius International Ltd. The technol...ward in wireless communication from Frost & Su...
(Date:12/2/2009)...900 runners and walkers from Las Vegas and around ... ‘n’ Roll Las Vegas Half Marathon powe...he Crohn,s & Colitis Foundation through its ha...ccteamchallenge). As the official charity of the r... and support initiatives to benefit the 1.4 millio...
(Date:12/2/2009)...ire/ -- The American Health Information Management...Alan F. Dowling, PhD, will be the next chief execu...ement (HIM) leader. Dr. Dowling,s extensive healt...s management, strategic expertise, governance and ... He is scheduled to take office January 13, 2010....
(Date:12/2/2009)...SNewswire/ -- Pro-abortion activists will lobby Wa...n against the U.S. House bill,s pro-life Stupak-Pi...esident and CEO Charmaine Yoest released this stat...o expand taxpayer funding of abortion: ,, "By c...roups and the abortion lobby actually demean women...
(Date:12/2/2009)... Highlights Dangers ,, WASHINGTON, Dec. 2 /P...s have their way, many medical treatments and prev... threat. The pressure that the US bishops have br... has been widely reported. An ad in this morning,s...hat pressure to influence healthcare policy is not...
Breaking Medicine News(10 mins):Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2[0] New AERIUS Cell Phones Direct Microwave Signals Away from Users [0] Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis[0] Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer[0] Pro-Life Response to the Abortion Lobby's "National Day of Action" Effort to Fight the Stupak-Pitts Amendment[2] Everybody's Healthcare Is Threatened by Catholic Bishops' Interference
SizingMergesLeadersCitizensSubmissionsStrandwareOASYSNettlesPushingJourneyTransformingOptimisticReallyOffshore
Other Tagsreview 2review 3review 4review 5review 6review 7review 8review 9review 10speed 2speed 3speed 4speed 5speed 6speed 7speed 8speed 9speed 10plastic 2plastic 3plastic 4plastic 5plastic 6plastic 7plastic 8plastic 9plastic 10smart 2smart 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |